Interleukin-17: Friend or foe in organ fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Fibrosis affects all vital organs accounting for a staggering 45% of deaths worldwide and no effective therapies are currently available. Unresolved inflammation triggers downstream signaling events that lead to organ fibrosis. In recent years, proinflammatory cytokine Interleukin-17 (IL-17) has been implicated in several chronic inflammatory diseases that often culminate in organ damage followed by impaired wound healing and fibrosis. In this review, we outline the contribution of the IL-17 in mediating fibrotic diseases in various organs. A comprehensive understanding of the inflammatory events, and particularly the details of IL-17 signaling in vivo, could be beneficial in designing new therapeutic or preventive approaches to treat fibrosis. Additionally, understanding organ-specific differences in IL-17 activity could lead to targeted therapies and help spare other organs from unwanted side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 4×
“Gene products induced by IL-17 include cytokines (IL-6, GM-CSF, TNFα), chemokines (CXCL1, CXCL2, CCL20) and inflammatory effectors (acute-phase proteins, complement), all of which can act as profibrotic factors in organ fibrosis [3, 21].”
BackgroundInfluentialLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056 · cited 5×
“It has also been shown to appear without any underlying cause, termed as idiopathic pulmonary fibrosis (IPF) [31].”
BackgroundInfluentialPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 5×
“In contrast, under inflammatory settings where IFN-γ (Th1 cytokine) dominates, organ fibrosis is attenuated [2, 17, 18].”
BackgroundInfluentialThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295 · cited 1×
“HSC is a highly regulated process involving multiple cytokines and growth factors produced by liver infiltrating immune cells and hepatic cells [64, 65].”
BackgroundHepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
IL-17 Signaling: The Yin and the Yang
Amatya, N., Garg, A. V., & Gaffen, S. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.006 · Cited by 785
A protective function for interleukin 17A in T cell–mediated intestinal inflammation
O'Connor Jr, W., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, Y., Kolls, J. K., & Flavell, R. A. (2009) · Nature Immunology · doi:10.1038/ni.1736 · Cited by 756
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 3×
“IL-17 also drives the production of type I collagen in hepatic stellate cells in a Stat3 dependent manner [66].”
BackgroundIL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis
Hams, E., Armstrong, M. E., Barlow, J. L., Saunders, S. P., Schwartz, C., Cooke, G., Fahy, R. J., Crotty, T. B., Hirani, N., Flynn, R. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315854111 · Cited by 376 · cited 1×
“pulmonary expression of IL-25, previously implicated in the Schistosoma mansoni-induced pulmonary fibrosis, was also noted in IPF patients [45].”
BackgroundCytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375 · cited 2×
“In contrast, under inflammatory settings where IFN-γ (Th1 cytokine) dominates, organ fibrosis is attenuated [2, 17, 18].”
BackgroundMi, S., Li, Z., Yang, H.-Z., Liu, H., Wang, J.-P., Ma, Y.-G., Wang, X.-X., Liu, H.-Z., Sun, W., & Hu, Z.-W. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004081 · Cited by 370 · cited 2×
“Several studies have revealed an association between IL-17 family of cytokines and pulmonary fibrosis [33-38].”
BackgroundIL-1 and IL-23 Mediate Early IL-17A Production in Pulmonary Inflammation Leading to Late Fibrosis
Gasse, P., Riteau, N., Vacher, R., Michel, M.-L., Fautrel, A., di Padova, F., Fick, L., Charron, S., Lagente, V., Eberl, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023185 · Cited by 208 · cited 1×
“Several studies have revealed an association between IL-17 family of cytokines and pulmonary fibrosis [33-38].”
BackgroundOh, K., Park, H.-B., Byoun, O.-J., Shin, D.-M., Jeong, E. M., Kim, Y. W., Kim, Y. S., Melino, G., Kim, I.-G., & Lee, D.-S. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101457 · Cited by 118 · cited 1×
“Additionally, transglutaminase 2, a calciumdependent enzyme that catalyzes the cross-linking of proteins, produced by lung epithelial and fibroblast cells is absolutely required for IL-17 production from lung infiltrating T cells during BLM-induced fibrosis [43, 44].”
BackgroundB cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis
François, A., Gombault, A., Villeret, B., Alsaleh, G., Fanny, M., Gasse, P., Adam, S. M., Crestani, B., Sibilia, J., Schneider, P., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.08.003 · Cited by 109 · cited 1×
“Several reports have identified that BLM-induced IL-17 production was TGF-β and IL-1 dependent, suggesting cooperative roles for IL-17, TGF-β and IL-1 in the development of fibrosis [3, 33], More recently, B cell activating factor (BAFF) has been shown to be involved in a crosstalk with IL-17 in the pathogenesis of lu…”
BackgroundChen, Y., Li, C., Weng, D., Song, L., Tang, W., Dai, W., Yu, Y., Liu, F., Zhao, M., Lu, C., et al. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.11.012 · Cited by 75
Role of interleukin 17 in TGF-β signaling-mediated renal interstitial fibrosis
Sun, B., Wang, H., Zhang, L., Yang, X., Zhang, M., Zhu, X., Ji, X., & Wang, H. (2018) · Cytokine · doi:10.1016/j.cyto.2017.10.015 · Cited by 47
Neutralization of Interleukin‐17 Attenuates Cholestatic Liver Fibrosis in Mice
Zhang, S., Huang, D., Weng, J., Huang, Y., Liu, S., Zhang, Q., Li, N., Wen, M., Zhu, G., Lin, F., et al. (2016) · Scandinavian Journal of Immunology · doi:10.1111/sji.12395 · Cited by 36
Interleukin-17A antagonist attenuates radiation-induced lung injuries in mice
Wang, B.-Z., Wang, L.-P., Han, H., Cao, F.-L., Li, G.-Y., Xu, J.-L., Wang, X.-W., & Wang, L.-X. (2014) · Experimental Lung Research · doi:10.3109/01902148.2013.872210 · Cited by 33
Cited by
Targeting the progression of chronic kidney disease
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0248-y · Cited by 979
The senescence-associated secretory phenotype and its physiological and pathological implications
Wang, B., Han, J., Elisseeff, J. H., & Demaria, M. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00727-x · Cited by 948
Targeting interleukin-17 as a novel treatment option for fibrotic diseases
Sisto, M., & Lisi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010164 · Cited by 22
Metadata
- Authors
- Ramani, K., & Biswas, P. S.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 120
- Pages
- 282-288
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2911411032
- Cited by
- 66
- References
- 21
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.